Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298087 · ClinicalTrials.gov registry record · Phase 2
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03298087: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03298087 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03298087, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
Interventions
- RADIATION stereotactic body radiotherapy
- DRUG Leuprolide
- DRUG apalutamide
- PROCEDURE radical prostatectomy
- DRUG abiraterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03298087
The ClinicalTrials.gov registry entry for NCT03298087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which stereotactic body radiotherapy is the first listed.
NCT03298087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03298087 about?
NCT03298087 is a clinical study titled "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer". This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
What is the current status of trial NCT03298087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-07-01. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03298087?
The interventions under investigation include: stereotactic body radiotherapy (RADIATION), Leuprolide (DRUG), apalutamide (DRUG), radical prostatectomy (PROCEDURE), abiraterone (DRUG).
Who is sponsoring clinical trial NCT03298087?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.